11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaene

01/01/2023 - "Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib."
01/01/2021 - "Therefore, our data may help to identify those patients with myelofibrosis who may benefit from pacritinib treatment."
11/01/2016 - "The development, safety and efficacy of pacritinib for the treatment of myelofibrosis."
11/01/2022 - "The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST-2 studies. "
11/24/2020 - "Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis."

01/01/2022 - "These results indicate that pacritinib is a promising treatment for patients with MF who lack safe and effective therapeutic options due to severe thrombocytopenia."
01/01/2022 - "Pacritinib, with its unique mechanism of action targeting both JAK2 and IRAK1, offers patients with MF and severe thrombocytopenia a new treatment option, providing consistent disease and symptom control. "
01/01/2022 - "This review will outline the pacritinib drug profile and summarize key efficacy and safety data, focusing on the 200 mg twice daily dose from phase 2 and 3 studies that formed the basis for the recent US Food and Drug Administration approval of pacritinib in patients with MF and severe thrombocytopenia (platelet counts <50 × 109/L). "
12/01/2022 - "Recently, pacritinib was approved for patients with MF and extreme thrombocytopenia. "
01/01/2018 - "Expert commentary: Pacritinib has demonstrated promising results in patients with myelofibrosis and thrombocytopenia. "

04/01/2018 - "Pacritinib, a dual JAK2 and FLT3 inhibitor which also inhibits IRAK1, has demonstrated the ability to favorably impact MF-associated splenomegaly and symptom burden, while having limited myelosuppression with manageable gastrointestinal toxicity. "
01/01/2023 - "Previously, patients with severe thrombocytopenia had limited treatment options; approval of pacritinib offers an option to address splenomegaly and/or symptoms in these patients. "
01/01/2015 - "Pacritinib, a dual JAK2 and FLT3 inhibitor, improves disease-related symptoms and signs with manageable gastrointestinal toxicity in patients with myelofibrosis with splenomegaly and high-risk features, without causing overt myelosuppression, and therefore may provide an important treatment option for a range of patients with myelofibrosis. "
11/01/2011 - "SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2(V617F)-driven disease model. "
01/01/2021 - "Pacritinib was less effective on splenomegaly than ruxolitinib as a first-line treatment but seemed effective in second line, after ruxolitinib exposure. "

10/10/2023 - "These data indicate that the anemia benefit of the JAK2/IRAK1 inhibitor pacritinib may be a function of potent ACVR1 inhibition."
10/10/2023 - "The impact of pacritinib on transfusion independence (TI) has not been previously described, nor has the mechanism by which pacritinib improves anemia been elucidated. "
10/10/2023 - "In patients with cytopenic myelofibrosis, treatment with the JAK2/IRAK1 inhibitor pacritinib was associated with anemia benefit in the phase 3 PERSIST-2 study. "
10/10/2023 - "Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis."
01/01/2018 - "For pacritinib once daily, pacritinib twice daily, and BAT, the most common (>10%) grade 3 or 4 adverse events were thrombocytopenia (32 patients [31%], 34 patients [32%], 18 patients [18%]), and anemia (28 patients [27%], 23 patients [22%], 14 patients [14%]). "

05/01/2022 - "As pacritinib is a Jak2 inhibitor currently in phase III clinical trials, our findings may facilitate the application of this co-treatment in patients with MDR cancer."
12/08/2016 - "In the phase 1 dose-escalation part of the study, 43 adults with advanced myeloid malignancies received pacritinib 100 to 600 mg once daily (QD). "
05/01/2022 - "Co-treatment of Low Dose Pacritinib, a Phase III Jak2 Inhibitor, Greatly Increases Apoptosis of P-gp Over-expressing Cancer Cells With Multidrug Resistance."
01/01/2022 - "IRAK1 inhibitor pacritinib inhibit proliferation and upregulate PD-L1 expression in different cancer cell lines. "
07/02/2019 - "Pacritinib-mediated effects were accompanied by a reduction of oncomiR miR-21-5p, by which the tumor suppressor PDCD4 was targeted. "